Literature DB >> 24435071

Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia.

Jason R Tregellas, Jason Smucny, Josette G Harris, Ann Olincy, Keeran Maharajh, Eugene Kronberg, Lindsay C Eichman, Emma Lyons, Robert Freedman.   

Abstract

OBJECTIVE: Identification of biomarkers for cognitive dysfunction in schizophrenia is a priority for psychiatry research. Functional imaging studies suggest that intrinsic "resting state" hippocampal hyperactivity is a characteristic feature of schizophrenia. The relationships between this phenotype and symptoms of the illness, however, are largely unexplored. The authors examined resting hippocampal activity in schizophrenia patients and healthy comparison subjects and analyzed the relationship between intrinsic hippocampal activity and cognitive function in patients as measured by the MATRICS Consensus Cognitive Battery (MCCB).
METHOD: Twenty-eight schizophrenia patients and 28 age-matched healthy comparison subjects underwent functional "resting state" 3-T MR scanning. Hippocampal activity was extracted by group independent component analysis. Correlation analyses were used to examine the relationship between hippocampal activity and MCCB composite and domain scores in patients, as well as between hippocampal activity and positive and negative symptoms.
RESULTS: Greater activity of the right hippocampus at rest was observed in patients relative to comparison subjects. In patients, a significant negative correlation was observed between right hippocampal activity and composite MCCB T-score. The correlation was driven by the MCCB domains of attention/vigilance, working memory, and visual learning. Hippocampal activity was positively correlated with negative symptoms. MCCB scores were inversely correlated with negative symptoms.
CONCLUSIONS: These findings suggest that greater intrinsic hippocampal activity is a characteristic feature of schizophrenia that is broadly associated with cognitive dysfunction, and they support hippocampal activity as a candidate biomarker for therapeutic development.

Entities:  

Mesh:

Year:  2014        PMID: 24435071      PMCID: PMC4085164          DOI: 10.1176/appi.ajp.2013.13070981

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  53 in total

1.  Resting-state perfusion in nonmedicated schizophrenic patients: a continuous arterial spin-labeling 3.0-T MR study.

Authors:  Lukas Scheef; Christoph Manka; Marcel Daamen; Kai-Uwe Kühn; Wolfgang Maier; Hans H Schild; Frank Jessen
Journal:  Radiology       Date:  2010-05-26       Impact factor: 11.105

2.  Centenary of Brodmann's map--conception and fate.

Authors:  Karl Zilles; Katrin Amunts
Journal:  Nat Rev Neurosci       Date:  2010-01-04       Impact factor: 34.870

Review 3.  Neuroimaging studies of the hippocampus in schizophrenia.

Authors:  S Heckers
Journal:  Hippocampus       Date:  2001       Impact factor: 3.899

4.  Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.

Authors:  Richard S E Keefe; Sophia Vinogradov; Alice Medalia; Peter F Buckley; Stanley N Caroff; Deepak C D'Souza; Phillip D Harvey; Karen A Graham; Robert M Hamer; Stephen M Marder; Del D Miller; Stephen J Olson; Jayendra K Patel; Dawn Velligan; Trina M Walker; Adam J Haim; T Scott Stroup
Journal:  J Clin Psychiatry       Date:  2012-05-15       Impact factor: 4.384

5.  Temporolimbic volume reductions in schizophrenia.

Authors:  R E Gur; B I Turetsky; P E Cowell; C Finkelman; V Maany; R I Grossman; S E Arnold; W B Bilker; R C Gur
Journal:  Arch Gen Psychiatry       Date:  2000-08

Review 6.  A review of MRI findings in schizophrenia.

Authors:  M E Shenton; C C Dickey; M Frumin; R W McCarley
Journal:  Schizophr Res       Date:  2001-04-15       Impact factor: 4.939

7.  Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.

Authors:  Scott A Schobel; Nashid H Chaudhury; Usman A Khan; Beatriz Paniagua; Martin A Styner; Iris Asllani; Benjamin P Inbar; Cheryl M Corcoran; Jeffrey A Lieberman; Holly Moore; Scott A Small
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

8.  The effect of distracting noise on the neuronal mechanisms of attention in schizophrenia.

Authors:  Jason R Tregellas; Jason Smucny; Lindsay Eichman; Donald C Rojas
Journal:  Schizophr Res       Date:  2012-10-09       Impact factor: 4.939

9.  Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia.

Authors:  Cynthia Z Burton; Lea Vella; Philip D Harvey; Thomas L Patterson; Robert K Heaton; Elizabeth W Twamley
Journal:  Schizophr Res       Date:  2013-03-15       Impact factor: 4.939

10.  Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.

Authors:  Xiang Yang Zhang; Lei Liu; Shaowen Liu; Xiaohong Hong; Da Chun Chen; Mei Hong Xiu; Fu De Yang; Zhijun Zhang; Xiangrong Zhang; Therese A Kosten; Thomas R Kosten
Journal:  Am J Psychiatry       Date:  2012-09       Impact factor: 18.112

View more
  61 in total

1.  Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.

Authors:  Ming Teng Koh; Yi Shao; Sharon Rosenzweig-Lipson; Michela Gallagher
Journal:  Schizophr Res       Date:  2017-06-17       Impact factor: 4.939

2.  Nicotinic modulation of salience network connectivity and centrality in schizophrenia.

Authors:  Jason Smucny; Korey P Wylie; Eugene Kronberg; Kristina T Legget; Jason R Tregellas
Journal:  J Psychiatr Res       Date:  2017-02-03       Impact factor: 4.791

3.  Energization by multiple substrates and calcium challenge reveal dysfunctions in brain mitochondria in a model related to acute psychosis.

Authors:  Jamila Monteiro; Gabriela Assis-de-Lemos; Eduardo de-Souza-Ferreira; Adriana M Marques; Gilda A Neves; Mariana S Silveira; Antonio Galina
Journal:  J Bioenerg Biomembr       Date:  2019-12-18       Impact factor: 2.945

4.  Neuronal effects of nicotine during auditory selective attention in schizophrenia.

Authors:  Jason Smucny; Ann Olincy; Donald C Rojas; Jason R Tregellas
Journal:  Hum Brain Mapp       Date:  2015-10-31       Impact factor: 5.038

5.  Hippocampal-parietal dysconnectivity and glutamate abnormalities in unmedicated patients with schizophrenia.

Authors:  Nina Vanessa Kraguljac; David Matthew White; Jennifer Hadley; Meredith Amanda Reid; Adrienne Carol Lahti
Journal:  Hippocampus       Date:  2014-08-01       Impact factor: 3.899

Review 6.  Functional magnetic resonance imaging of intrinsic brain networks for translational drug discovery.

Authors:  Jason Smucny; Korey P Wylie; Jason R Tregellas
Journal:  Trends Pharmacol Sci       Date:  2014-06-03       Impact factor: 14.819

7.  Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia.

Authors:  Wei Li; Subroto Ghose; Kelly Gleason; Anita Begovic; Jessica Perez; John Bartko; Scott Russo; Anthony D Wagner; Lynn Selemon; Carol A Tamminga
Journal:  Am J Psychiatry       Date:  2015-01-13       Impact factor: 18.112

8.  P50 inhibitory sensory gating in schizophrenia: analysis of recent studies.

Authors:  Robert Freedman; Amanda M Olsen-Dufour; Ann Olincy
Journal:  Schizophr Res       Date:  2020-02-13       Impact factor: 4.939

9.  Metabolic Abnormalities in the Hippocampus of Patients with Schizophrenia: A 3D Multivoxel MR Spectroscopic Imaging Study at 3T.

Authors:  E J Meyer; I I Kirov; A Tal; M S Davitz; J S Babb; M Lazar; D Malaspina; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-21       Impact factor: 3.825

Review 10.  Brain circuit dysfunction in a distinct subset of chronic psychotic patients.

Authors:  Morris B Goldman
Journal:  Schizophr Res       Date:  2014-07-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.